Tom H M Ottenhorf

Title: Tom H M Ottenhorf: Innovator in Immunology

Introduction

Tom H M Ottenhorf is a notable inventor based in Oegstgeest, Netherlands. He has made significant contributions to the field of immunology, particularly in the development of peptides that enhance immune responses against viral infections and tumors. His work is crucial in advancing therapeutic strategies for diseases such as cervical cancer.

Latest Patents

Ottenhorf holds a patent for "Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses." This invention focuses on epitopes derived from the human papilloma virus (HPV). The patent describes peptides that are 22 to 45 amino acids in length, which include minimal T cell epitopes. The invention outlines clinically relevant methods for immunizing individuals against (Myco)bacterially and/or virally infected cells, particularly targeting HPV. It demonstrates that peptide sequences of 22 to 35 amino acids can induce both CD8+ cytolytic cells and CD4+ T-helper cells. Furthermore, the invention shows that vaccination with these longer peptides results in a more robust CD8+ cytolytic T-cell response compared to shorter peptides. It also addresses the challenge of certain minimal CTL epitopes that may tolerize cytolytic cells, providing a solution through the use of longer peptides. This patent is pivotal for the vaccination and treatment of subjects suffering from progressive lesions and cervical cancer.

Career Highlights

Ottenhorf is affiliated with Academisch Ziekenhuis Leiden, where he continues to contribute to research and development in immunology. His work has implications for improving vaccine efficacy and therapeutic approaches for viral infections and cancer.

Collaborations

Ottenhorf collaborates with esteemed colleagues such as Sjoerd Hendrikus Van Der Burg and Annemieke Geluk. Their combined expertise enhances the research efforts in the field of immunology.

Conclusion

Tom H M Ottenhorf is a distinguished inventor whose work in peptide-based immunotherapy is paving the way for innovative treatments against HPV and related diseases. His contributions are vital for advancing medical science and improving patient outcomes.